瑞士的乳腺癌:组织查与机会查州之间的比较
A Gutzeit1, P Dubsky2, S Matoori3
1Department of Radiology and Nuclear Medicine, Cantonal hospital Schaffhausen, Schaffhausen; University of Lucerne, Department of Health Sciences and Medicine, Lucerne.
ESMO open
|September 25, 2024
概括
在没有有组织的乳腺癌查的瑞士地区,50-69岁的女性患有更大的瘤和更多的淋巴结转移. 这突显了有组织的乳房造影查计划对于早期发现乳腺癌的好处.
科学领域:
- 在瘤学瘤学.
- 公共卫生 公共卫生
- 放射学 放射学是一门学科.
背景情况:
- 瑞士缺乏统一的国家乳腺癌查计划.
- 大多数州都有乳房扫描查,但瑞士中部没有.
- 这项研究比较了有组织和机会性查区域之间的乳腺癌TNM状态.
研究的目的:
- 在瑞士,通过有组织的查检测到的乳腺癌的TNM (瘤结节转移) 状态与机会性查进行比较.
- 评估不同乳腺癌查策略对乳腺癌检测和分期的影响.
主要方法:
- 从2014年到2020年期间,从国家癌症登记处获得的TNM数据的回顾性比较.
- 来自有组织查 (Or-SC) 的州的数据与没有组织查 (Op-SC) 的州的数据进行了比较.
- 患者队列按年龄组分为两层:<50,50-69岁和>70岁.
主要成果:
- 在机会性查州 (Op-SC) 的50-69岁女性中,瘤显著增加 (T1-3).
- 在Op-SC组中,节点阴性 (N0) 乳腺癌的比例显著降低.
- 两组之间没有观察到远程转移 (M状态) 的显著差异.
结论:
- 与有组织查地区的患者相比,在机会性查地区的50-69岁患者呈现出更大的瘤和更多的淋巴结参与.
- 这些发现强调了有组织的乳腺癌查计划的优势,以改善早期检测和患者的治疗结果.
- 这项研究为高收入国家查战略有效性提供了独特的见解.
更多相关视频
06:19Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
Published on: June 16, 2023
3.1K
08:30Mammary Epithelial and Endothelial Cell Spheroids as a Potential Functional In vitro Model for Breast Cancer Research
Published on: July 12, 2021
4.5K
相关概念视频
02:46Genetic Screens
4.9K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
4.9K
01:21Cancer Survival Analysis
331
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
331